Chinyu Su

7.6k total citations · 3 hit papers
150 papers, 5.8k citations indexed

About

Chinyu Su is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Chinyu Su has authored 150 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Genetics, 87 papers in Epidemiology and 52 papers in Surgery. Recurrent topics in Chinyu Su's work include Inflammatory Bowel Disease (118 papers), Microscopic Colitis (78 papers) and Biosimilars and Bioanalytical Methods (24 papers). Chinyu Su is often cited by papers focused on Inflammatory Bowel Disease (118 papers), Microscopic Colitis (78 papers) and Biosimilars and Bioanalytical Methods (24 papers). Chinyu Su collaborates with scholars based in United States, Spain and Canada. Chinyu Su's co-authors include Julián Panés, William J. Sandborn, Gary R. Lichtenstein, Nervin Lawendy, Wojciech Niezychowski, James D. Lewis, Bruce E. Sands, Gary S. Friedman, Haiying Zhang and Silvio Danese and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Gastroenterology.

In The Last Decade

Chinyu Su

147 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

2017 1.2k citations William J. Sandborn, Chinyu Su et al. profile →
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response

1999 665 citations Chinyu Su et al. profile →
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

2012 643 citations William J. Sandborn, Julián Panés et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chinyu Su United States	32	3.8k	2.7k	1.4k	1.1k	864	150	5.8k
Colleen Marano United States	31	3.9k 1.0×	3.0k 1.1×	1.2k 0.8×	1.8k 1.6×	443 0.5×	119	5.6k
R. A. van Hogezand Netherlands	33	3.7k 1.0×	2.7k 1.0×	2.2k 1.5×	1.1k 1.0×	551 0.6×	74	5.8k
Niels Vande Casteele United States	43	5.1k 1.3×	3.6k 1.4×	1.2k 0.8×	2.9k 2.6×	579 0.7×	158	6.8k
Íngrid Ordás Spain	31	4.6k 1.2×	3.2k 1.2×	2.2k 1.5×	1.1k 1.0×	221 0.3×	86	6.3k
Kiron M. Das United States	36	1.8k 0.5×	1.4k 0.5×	1.7k 1.2×	910 0.8×	413 0.5×	197	4.7k
Κωνσταντίνος Κατσάνος Greece	28	2.8k 0.7×	2.0k 0.7×	1.2k 0.8×	727 0.6×	237 0.3×	60	3.8k
Konstantinos Κarmiris Greece	23	2.1k 0.5×	1.7k 0.6×	753 0.5×	708 0.6×	222 0.3×	60	3.2k
Bernard Duclos France	31	2.1k 0.5×	1.6k 0.6×	922 0.6×	576 0.5×	246 0.3×	100	3.6k
Roopal Thakkar United States	29	3.1k 0.8×	2.7k 1.0×	1.5k 1.0×	646 0.6×	297 0.3×	142	5.3k
Christopher L. Bowlus United States	53	648 0.2×	4.0k 1.5×	3.2k 2.2×	870 0.8×	593 0.7×	231	8.9k

Countries citing papers authored by Chinyu Su

Since Specialization

Citations

This map shows the geographic impact of Chinyu Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chinyu Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chinyu Su more than expected).

Fields of papers citing papers by Chinyu Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chinyu Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chinyu Su. The network helps show where Chinyu Su may publish in the future.

Co-authorship network of co-authors of Chinyu Su

This figure shows the co-authorship network connecting the top 25 collaborators of Chinyu Su. A scholar is included among the top collaborators of Chinyu Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chinyu Su. Chinyu Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lichtenstein, Gary R., Benjamin L. Cohen, Leonardo Salese, et al.. (2023). Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis. Digestive Diseases and Sciences. 68(6). 2624–2634. 1 indexed citations

Schreiber, Stefan, David T. Rubin, Siew C. Ng, et al.. (2023). Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. Journal of Crohn s and Colitis. 17(11). 1761–1770. 17 indexed citations

Winthrop, Kevin, Arne Yndestad, Dan Henrohn, et al.. (2022). Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and Therapy. 10(2). 357–373. 3 indexed citations

Loftus, Edward V., Daniel C. Baumgart, K Gecse, et al.. (2022). Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program. Inflammatory Bowel Diseases. 29(5). 744–751. 3 indexed citations

Panés, Julián, Séverine Vermeire, Marla C. Dubinsky, et al.. (2021). Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. Journal of Crohn s and Colitis. 15(11). 1852–1863. 20 indexed citations

Feagan, Brian G., Reena Khanna, William J. Sandborn, et al.. (2021). Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Alimentary Pharmacology & Therapeutics. 54(11-12). 1442–1453. 11 indexed citations

Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(9). 3214–3215. 1 indexed citations

Rubin, David T., Marla C. Dubinsky, Silvio Danese, et al.. (2020). Tu1866 EFFICACY AND SAFETY OF AN ADDITIONAL 8 WEEKS OF TOFACITINIB INDUCTION THERAPY: UPDATED RESULTS OF THE OCTAVE OPEN STUDY FOR TOFACITINIB 8-WEEK INDUCTION NON-RESPONDERS. Gastroenterology. 158(6). S–1194. 1 indexed citations

Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(8). 2732–2743. 11 indexed citations

10.

Sandborn, William J., Laurent Peyrin‐Biroulet, Daniel Quirk, et al.. (2020). Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20(8). 1821–1830.e3. 54 indexed citations

11.

Colombel, J F, Mark T. Osterman, Patricio Ibáñez, et al.. (2020). DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open. Journal of Crohn s and Colitis. 14(Supplement_1). S098–S099. 2 indexed citations

12.

Sands, Bruce E., Alessandro Armuzzi, John K. Marshall, et al.. (2019). Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology & Therapeutics. 51(2). 271–280. 65 indexed citations

13.

Hanauer, Stephen B., Remo Panaccione, Silvio Danese, et al.. (2018). Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 17(1). 139–147. 132 indexed citations

14.

Bloom, Stuart, Gary R. Lichtenstein, Edward V. Loftus, et al.. (2018). PTU-001 Tofacitinib, an oral jak inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study. A62.2–A63. 1 indexed citations

15.

Dubinsky, Marla C., Laurent Peyrin‐Biroulet, Gil Melmed, et al.. (2017). Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies. The American Journal of Gastroenterology. 112. S354–S354. 11 indexed citations

16.

Panés, Julián, David T. Rubin, Séverine Vermeire, et al.. (2017). P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis. Journal of Crohn s and Colitis. 11(suppl_1). S315–S317. 2 indexed citations

17.

Sandborn, William J., Julián Panés, Haiying Zhang, et al.. (2013). Tu1109 Evaluation of the Relationship Between Fecal Calprotectin Concentrations and Clinical and Endoscopic Outcome Measures in a Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. Gastroenterology. 144(5). S–764. 6 indexed citations

18.

Chamberlain, Bruce, Jaron L. Winston, James Thomas, et al.. (2009). Methylnaltrexone Treatment of Opioid-Induced Constipation in Patients with Advanced Illness. Journal of Pain and Symptom Management. 38(5). 683–690. 61 indexed citations

19.

Su, Chinyu, Gary R. Lichtenstein, Karen Krok, Colleen Brensinger, & James D. Lewis. (2004). A meta-analysis of the placebo rates of remission and response in clinical trials of active crohn’s disease. Gastroenterology. 126(5). 1257–1269. 161 indexed citations

20.

Su, Chinyu, Thomas Judge, & Gary R. Lichtenstein. (2002). Extraintestinal manifestations of inflammatory bowel disease. Gastroenterology Clinics of North America. 31(1). 307–327. 174 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact